Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
We have a wide range of fun and festive designs to choose from. Fund life changing research while spreading joy this Christmas!
This Christmas, your gift can bring us closer to a cure for type 1 diabetes – and every pound you give to our Christmas Appeal will be doubled.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This event is designed for anyone living with type 1 diabetes who would like to learn more about managing their wellbeing across a variety of contexts.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > Knowledge & support > Resource hub > Five research highlights from EASD conference 2023
At the beginning of October, Hamburg, Germany was filled with leading diabetes experts from over 120 countries, who had flocked there for Europe’s largest diabetes conference, EASD. Our Research Communications Lead, Josie Clarkson, attended the annual conference to bring you the latest updates in diabetes research.
While Josie was in Hamburg, we shared exciting JDRF news stories presented at the conference, which you can find on our news page. In this blog, she shares five more type 1 diabetes research highlights from the jam-packed week of science.
Hypos are a scary part of having type 1 – especially when they occur during the night. So, JDRF has been supporting clinical trials of a drug called ZT-01 which can help prevent hypos by restoring glucagon activity. Glucagon is a hormone that counteracts insulin, when glucose levels drop too low, glucagon triggers glucose release from the liver into the blood to avoid hypos.
A new clinical trial called ZONE is testing ZT-01 in people with type 1 diabetes. The researchers are recruiting adults aged 18-75 across the US and gave the first dose of ZT-01 in September 2023. The people who take part will receive a daily injection of either the low, medium or high dose of ZT-01 for 28 days and a placebo for 28 days.
The researchers are mainly looking at how many nocturnal hypos the participants have but will also measure their time below range and any other hypos they experience. This exciting drug has the potential to protect against overnight hypos and help adults with type 1 to manage their blood glucose levels.
Complications of diabetes featured in several sessions at this year’s conference, with chronic kidney disease (CKD) a key topic of discussion. Research is underway into early detection and prevention of CKD, but there are many people with type 1 who are already living with CKD. On the third day of the conference, we heard about an upcoming clinical trial of a treatment for CKD in people with type 1.
FINE-ONE is a clinical trial of the drug finerenone, which is already approved on the NHS to lower the risk of kidney failure in people with type 2 diabetes. In FINE-ONE, researchers will test finerenone in 220 people with type 1 and CKD. The clinical trials will take place in several countries including the UK over six months. Find out more about FINE-ONE, including how to take part.
We were pleased to see diabetes distress recognised on such a big international stage with a session titled ‘Healing the feelings in type 1 diabetes’. Diabetes distress is defined as the range of emotional responses to managing diabetes, including feeling overwhelmed, defeated, worried and burnt out. But it’s not just the person diagnosed with type 1 who can experience diabetes distress, we heard how family members also experience physical and psychological complications of their loved ones’ diabetes.
Most parents of children with type 1 experience clinically significant depression and anxiety, especially in the first year after diagnosis, with up to 30% reporting clinical distress. Researchers found the main causes of this distress are fear of hypos, anxiety around long-term diabetes complications, and access to daily supplies. This can lead to caregivers being overprotective, prioritising their child’s blood glucose levels over creating an open dialogue with their child about their condition. Family distress is also linked to adolescents paying less attention to managing their diabetes, and children having higher HbA1c levels and less stable blood glucose levels.
This collection of research presents a new target to help treat type 1, with researchers encouraging diabetes healthcare professionals to pay more attention to the families of their patients with type 1. Supporting families of people with type 1 and monitoring general and diabetes-related family function can help improve diabetes care.
A photo of AdoShell®: islets (black dots) suspended in an immunoprotective gel.
Transplants of insulin-producing clusters of cells called islets, either grown in a lab or from a donor, are believed by many people to hold exciting potential as a cure for type 1 diabetes. Currently, people who receive islet transplants must take drugs to suppress their immune system so that it doesn’t destroy the new cells, but these drugs can have bad side effects.
Adoceia, a French biotech company, has developed a protective gel for islets, named AdoShell®, which keeps them safe from the immune system without the need for immunosuppressant drugs. AdoShell® is a semi-permeable soft coating, which lets insulin out but stops harmful immune cells getting in to attack the islets. Their researchers have been testing AdoShell® on human cells in petri dishes and in animals. The latest results from these trials were presented at the 2023 EASD conference.
The human islets encapsulated within AdoShell® responded to glucose by releasing insulin just as well as islets that weren’t in a protective coating, meaning the gel wasn’t interfering with the islets’ function. In some animals, this insulin release was still present seven months after the device was implanted. Because of the safety and effectiveness seen in their preclinical trials, Adocia is planning to run a clinical trial in people with type 1 in 2024.
Find out more about encapsulation on our Cure Research webpage.
Imagine if you only had to inject your basal insulin once a week instead of every single day. You may not need to imagine for much longer as Novo Nordisk announced the latest results from its ONWARDS clinical trials. At this year’s EASD, we heard the results, published in The Lancet, of their first large-scale study of 582 adults with type 1 comparing a daily insulin named degludec with a weekly insulin called icodec.
The researchers found no difference in the time in range or HbA1c between the people who took icodec vs those who took degludec. While these findings are promising, showing this weekly insulin is as effective as a daily insulin, icodec did lead to more hypos, although the overall rate of hypos among participants was low. These results provide important information about the safety and effectiveness of weekly insulin and inform the next round of icodec clinical trials.
We need more diversity among people taking part in clinical trials so that research findings are representative across populations.
Vertex is running a clinical trial in which people with type 1 diabetes receive a dose of VX-880, an investigational product that contains lab-grown islet cells.
"We need research to understand why rates of type 1 are rising"
We recently sent an open letter to the organisers of the Roland Garros Tennis Tournament. The letter expresses our strong concerns about the treatment of Alex Zverev, a professional tennis player and an individual living with type 1 diabetes.
Our research is improving the lives of people with type 1 and making strides towards a cure. We’ll keep pushing until we make type 1 diabetes a thing of the past.